ArticleCureus2025
Diagnostic Utility of Automated Breast Volume Scan in Differentiating Benign and Malignant Breast Masses.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to compare the diagnostic value of Automated Breast Volume Scan (ABVS) and Hand-Held Ultrasound (HHUS) in the characterization of breast masses and in differentiating benign and malignant breast masses. This is a prospective study on 101 patients with breast masses referred for ultrasound-guided biopsy. All patients underwent both HHUS (routine breast ultrasound) and ABVS of bilateral breasts and were classified according to the Breast Imaging-Reporting and Data System (BI-RADS). All ultrasound parameters to assess the lesions were compared for sensitivity, specificity, and accuracy between the two modalities. All the patients enrolled underwent ultrasound-guided biopsy of the breast lesions. One hundred eight breast lesions were identified and characterized in the 101 patients studied. The negative predictive value (NPV) of BIRADS-3 lesions in excluding malignancy was 82.6% and 90% by HHUS and ABVS, respectively. The positive predictive value (PPV) of BIRADS-5 lesions in predicting malignancy was 94.7% and 98.4% by HHUS and ABVS, respectively. The two ultrasound (US) modalities showed substantial agreement (k = 0.613). The most sensitive lesion characteristic suggesting malignancy was found to be irregular shape on both ABVS and HHUS. The retraction phenomenon identified in the coronal plane of ABVS was 100% specific and had a PPV of 100% in predicting a malignant lesion. As the diagnostic accuracy is similar in both modalities for breast masses, ABVS proves to be a promising diagnostic tool for breast lesions with the advantages of being reproducible, operator-independent, and standardized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.